Clinical Trial Applications: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | |
|---|---|---|---|---|
76. |
ECCT/19/01/01 | A Randomized, Open, Parallel-group, Single Dose, Phase 2a Study, to Investigate the Clinical and Parasiticidal Activity and the Pharmacokinetics of 3 dose levels of Artefenomel in combination with Ferroquine (FQ) and FQ alone, in African Patients with Unc A Randomized, Open label, Parallel-group, Single Dose Regimen, Phase 2a Study, to Investigate the Clinical and Parasiticidal Activity and the Pharmacokinetics of 3 dose levels of Artefenomel (OZ439) given in combination with Ferroquine (FQ) and FQ alone, in African Patients with Uncomplicated Plasmodium falciparum Malaria |
Principal Investigator(s) 1. Bernhards Ogutu Ragama Site(s) in Kenya 1. Ahero County hospital (Kisumu county) 2. Siaya County Hospital (Siaya county) |
View |
77. |
ECCT/18/07/02 | CONRAD RING Phase IIa, 90-Day Safety, Adherence, and Acceptability Study of Intravaginal Rings Releasing Tenofovir with and without Levonorgestrel among Women in Western Kenya |
Principal Investigator(s) 1. DR. NELLY RWAMBA MUGO Site(s) in Kenya KEMRI CRC |
View |
78. |
ECCT/18/06/04 | RANDOMIZED CONTROLLED TRIAL OF STEPPED UP VITAMIN A SUPPLEMENTATION DOSE ON IMMUNE RESPONSES AMONG INFANTS 6-12 MONTHS AT BUSIA LEVEL 4 HOSPITAL IN BUSIA COUNTY, KENYA BUSIA LEVEL IV HOSPITAL |
Principal Investigator(s) 1. BENARD OCHIENG WESONGA Site(s) in Kenya Busia Level IV Hospital |
View |
79. |
ECCT/18/07/07 | A Randomized, Open, Parallel-group, Single Dose, Phase 2a Study, to Investigate the Clinical and Parasiticidal Activity and the Pharmacokinetics of 3 dose levels of Artefenomel in combination with Ferroquine (FQ) and FQ alone, in African Patients with Unc A Randomized, Open label, Parallel-group, Single Dose Regimen, Phase 2a Study, to Investigate the Clinical and Parasiticidal Activity and the Pharmacokinetics of 3 dose levels of Artefenomel (OZ439) given in combination with Ferroquine (FQ) and FQ alone, in African Patients with Uncomplicated Plasmodium falciparum Malaria |
Principal Investigator(s) 1. GRACE KIRINGA KAGUTHI Site(s) in Kenya 1. Center for Respiratory Diseases Research (Siaya county) 2. KEMRI (Kisumu county) |
View |
80. |
ECCT/18/04/01 | CKAF156 STUDY A Phase 2 interventional, multicenter, randomized open-label study to determine the effective and tolerable dose of KAF156 and Lumefantrine Solid Dispersion Formulation in combination, given once daily for 1, 2 and 3-days to adults and children with uncomplicated Plasmodium falciparum malaria. |
Principal Investigator(s) 1. Bernhards Ogutu Site(s) in Kenya 1. KEMRI CDC (Siaya county) 2. Walter Reed Project (Kisumu county) |
View |